NY S09020

Establishes the "New York Affordable Drug Manufacturing Act of 2020" authorizing the Department of Health to enter into partnerships with drug manufacturers to produce and distribute generic prescription drugs at lower prices to increase competition and improve access.

Requires partnerships to produce at least one form of insulin (if viable pathways exist) and prioritize drugs for chronic and high-cost conditions, with pricing that considers FDA fees, abbreviated new drug application costs, production expenses, and reasonable administrative/operating costs amortized over five years.

Mandates all state agencies purchase prescription drugs from the department or its contracted partners, and requires the department to consult with state purchasers, health insurers, hospitals, and other entities to determine drug volumes and procurement needs.

Requires the department to submit a report by March 1, 2022 describing targeted drugs and analyzing the program's impact on competition, access, and costs, and a second report by January 1, 2023 assessing feasibility of direct manufacturing through various governance structures.

Protects nonpublic information and documents obtained by the department from disclosure under the state's Freedom of Information Law.